Schizophrenia

FDA to Review Lumateperone for Treatment of Schizophrenia

FDA to Review Lumateperone for Treatment of Schizophrenia

By

Lumateperone and follow-on compounds are also being evaluated for bipolar depression, behavioral disturbance associated with dementia, sleep disturbances associated with neuropsychiatric disorders, and other neuropsychiatric conditions including major depressive disorder and autism.

Polygenic Risk Scores May Predict Antipsychotic Efficacy in Schizophrenia

Polygenic Risk Scores May Predict Antipsychotic Efficacy in Schizophrenia

By

The use of a polygenic risk score for schizophrenia can effectively predict an antipsychotic treatment response after a first episode of psychosis.

Psychotic Experiences May Predict Future Suicidal Behaviors

Psychotic Experiences May Predict Future Suicidal Behaviors

By

Psychotic experiences may be a clinical marker of risk for future suicidal behaviors.

Link Between Sleep Disturbances and Inflammatory Markers in Schizophrenia

Link Between Sleep Disturbances and Inflammatory Markers in Schizophrenia

By

Investigators examined the relationship between sleep disturbances and levels of anti-inflammatory markers in patients with schizophrenia.

Link Between Low Insight, Metacognitive Impairment in Schizophrenia

Link Between Low Insight, Metacognitive Impairment in Schizophrenia

By

Awareness of self and others may provide insight into one's own psychiatric challenges.

Motion-Processing Deficits Linked to Impaired Cognitive Function in Schizophrenia

Motion-Processing Deficits Linked to Impaired Cognitive Function in Schizophrenia

By

New study data show a correlation between motion processing deficiency and cognitive impairment in patients with schizophrenia.

Perseris Now Available for the Treatment of Schizophrenia in Adults

Perseris Now Available for the Treatment of Schizophrenia in Adults

By

Perseris, an atypical antipsychotic, has an extended-release delivery system that releases sustained levels of risperidone over 1 month.

Quick Take: Association of Secondary Preventive Cardiovascular Treatment After Myocardial Infarction With Mortality Among Patients With Schizophrenia

Patients with schizophrenia have a shortened life expectancy of 15-20 years compared with the general population, with excess cardiac mortality contributing to this difference.

The Challenges of Identifying Biomarkers of Psychiatric Illness

The Challenges of Identifying Biomarkers of Psychiatric Illness

By

There is minimal overlap in neurologic variations among individuals with severe psychiatric conditions such as schizophrenia spectrum disorders and bipolar disorder.

Pathways for Intellectual Disability in Children: Maternal Mental Illness vs Obstetric Complications

Pathways for Intellectual Disability in Children: Maternal Mental Illness vs Obstetric Complications

By

Investigators sought to determine the relationship between familial severe mental illness vs obstetric complications and the risk for developing intellectual disability

Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia

Cardioprotective Treatment May Reduce Adverse Effects in Schizophrenia

By

Investigators sought to determine whether cardioprotective medication after a myocardial infarction could reduce mortality rates in patients with schizophrenia.

Clozapine Monotherapy May Be Effective in Reducing the Severity of Antipsychotic-Induced Tardive Dyskinesia

Clozapine Monotherapy May Be Effective in Reducing the Severity of Antipsychotic-Induced Tardive Dyskinesia

By

These results provide support for switching antipsychotics to clozapine in patients with moderate to severe tardive dyskinesia.

Long-term Treatment Outcomes With Aripiprazole Lauroxil in Schizophrenia

Long-term Treatment Outcomes With Aripiprazole Lauroxil in Schizophrenia

By

Safety, symptoms, and illness trajectory of outpatients with schizophrenia who received ongoing aripiprazole lauroxil were followed for 2 years.

Increased Adherence With Paliperidone Once Every 3 Months in Schizophrenia

Increased Adherence With Paliperidone Once Every 3 Months in Schizophrenia

By

Transition from a once-monthly formulation of a long-acting, injectable paliperidone palmitate to a once-every-3-month formulation treatment regimen in patients with schizophrenia demonstrated increased adherence to antipsychotic medication.

Brexpiprazole Appears Safe, Effective in Schizophrenia During Severe Psychotic Episodes

Brexpiprazole Appears Safe, Effective in Schizophrenia During Severe Psychotic Episodes

By

At 6 weeks of treatment, severely ill patients treated with adjunctive brexpiprazole had a greater reduction in PANSS total scores and CGI-S scores compared with those receiving placebo.

Latent Structure of Negative Symptoms in Schizophrenia Best Conceptualized by 5-Domain Model

Latent Structure of Negative Symptoms in Schizophrenia Best Conceptualized by 5-Domain Model

By

Existing 2-dimensional models are likely not sufficient to capture the complexity of negative symptoms in schizophrenia.

Moderate Association Between Sociocognitive Functioning and Thought Disorder in Schizophrenia

Moderate Association Between Sociocognitive Functioning and Thought Disorder in Schizophrenia

By

Interventions focused on emotion recognition may be effective in addressing sociocognitive deficits in patients with schizophrenia.

First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes

First-Episode Delusional Disorder vs Schizophrenia: Assessment of Outcomes

By

A team of UK-based investigators assessed functional and symptomatic outcomes in individuals with a first episode of psychotic disorder vs those associated with schizophrenia.

Prevalence of Schizophrenia in Individuals With Type 2 Diabetes

Prevalence of Schizophrenia in Individuals With Type 2 Diabetes

By

In an attempt to identify the risk associated with the comorbidity of type 2 diabetes and schizophrenia, a team of investigators from Taiwan assessed the impact of public health promotion efforts targeted at this population.

Metabolic Syndrome Predictive of Psychotic Relapse in Schizophrenia

Metabolic Syndrome Predictive of Psychotic Relapse in Schizophrenia

By

This research supports the monitoring of metabolic syndrome in patients with schizophrenia.

NDA Submitted for Novel Schizophrenia Treatment Lumateperone

NDA Submitted for Novel Schizophrenia Treatment Lumateperone

By

Lumateperone, a first-in-class molecule, works via potent interactions at 5-HT2A receptors, serotonin transporters, and D1 receptors with indirect glutamatergic modulation.

Moving Associated With Increased Risk for Psychosis in Children, Adolescents

Moving Associated With Increased Risk for Psychosis in Children, Adolescents

By

These data suggest that residential mobility may have a profound effect on the mental well-being of children and adolescents.

Clinical Markers Predict Resistance to Antipsychotic Therapy in Schizophrenia

Clinical Markers Predict Resistance to Antipsychotic Therapy in Schizophrenia

By

Timely categorization of patients as treatment-resistant or responsive may allow faster implementation of better targeted interventions.

Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations

Quetiapine Exposure Does Not Appear to Increase Risk for Infant Malformations

By

In conclusion, these preliminary findings suggest that quetiapine is not a teratogen and could be used safely during pregnancy, but further research is needed to completely understand the risks involved.

Psychosis Treatments

A comparative dosing and titration chart of commonly used first-generation and second-generation antipsychotics.

Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia

Associations Between Hypovitaminosis D and Poorer Outcomes in Schizophrenia

By

Future studies should investigate how supplementation with vitamin D may improve symptoms and outcomes.

Using Neurocognitive Profiles to Predict Conversion to Psychosis in High-Risk Patients

Using Neurocognitive Profiles to Predict Conversion to Psychosis in High-Risk Patients

By

The study exhibited an overall conversion rate of 35% to a psychotic disorder.

Remission of Schizophrenia Seen With Amisulpride, Clozapine

Remission of Schizophrenia Seen With Amisulpride, Clozapine

Remission can be achieved for most cases of schizophrenia and schizophreniform disorder with amisulpride and clozapine.

Symptoms of Sleep Disorders Prevalent in Psychiatric Illnesses

Symptoms of Sleep Disorders Prevalent in Psychiatric Illnesses

By

The authors argue that identifying and treating sleep disorders during early stages may have a positive impact on outcomes in psychiatric patients.

Reducing Off-Label Quetiapine Prescribing the Old-Fashioned Way: Snail Mail

Reducing Off-Label Quetiapine Prescribing the Old-Fashioned Way: Snail Mail

By

Despite the associated risk for death and cognitive decline, "off-label" prescribing of antipsychotics in patients with dementia has increased.

Sign Up for Free e-newsletters